Impact of KRASMutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Activating mutation of the KRAS oncogene is an established negative predictor for anti-epidermal growth factor receptor (anti-EGFR) therapies in metastatic colorectal cancer (CRC). However, KRAS mutation as a prognostic factor of survival outcome remains controversial in CRC, independent of anti-EGFR therapies. Materials and Methods We conducted a retrospective analysis of 103 CRC patients who were available for evaluation of KRAS mutation status. None of the patients analyzed had received anti-EGFR therapies. The role of KRAS mutation status was evaluated as a predictive factor for oxaliplatin or irinotecan and as a prognostic factor in CRC patients who did not receive anti-EGFR therapies. Results Mutations in KRAS were observed in 48.5% of patients. The response for oxaliplatin-(p=0.664) and irinotecan-based (p=0.255) cytotoxic chemotherapy did not differ according to the KRAS mutation status. In addition, no significant difference in progression free survival (PFS; oxaliplatin, p=0.583 and irinotecan, p=0.426) and overall survival (OS; p=0.258) was observed between the wild and mutant type of the KRAS gene. In univariate and multivariate analyses, KRAS mutations did not have a major prognostic value regarding PFS (oxaliplatin: hazard ratio, 0.892; 95% confidence interval [CI], 0.590 to 1.347; p=0.586 and irinotecan: hazard ratio, 0.831;95% CI, 0.524 to 1.319; p=0.433) or OS (hazard ratio, 0.754; 95% CI, 0.460 to 1.236; p=0.263). In addition, anti-vascular endothelial growth factor therapies did not affect PFS to oxaliplatin or irinotecan and OS. Conclusion KRAS mutation is not a prognostic marker for PFS to oxaliplatin or irinotecan and OS in CRC patients who did not receive anti-EGFR therapies.
Abstract
Purpose Activating mutation of the KRAS oncogene is an established negative predictor for anti-epidermal growth factor receptor (anti-EGFR) therapies in metastatic colorectal cancer (CRC). However, KRAS mutation as a prognostic factor of survival outcome remains controversial in CRC, independent of anti-EGFR therapies. Materials and Methods We conducted a retrospective analysis of 103 CRC patients who were available for evaluation of KRAS mutation status. None of the patients analyzed had received anti-EGFR therapies. The role of KRAS mutation status was evaluated as a predictive factor for oxaliplatin or irinotecan and as a prognostic factor in CRC patients who did not receive anti-EGFR therapies. Results Mutations in KRAS were observed in 48.5% of patients. The response for oxaliplatin-(p=0.664) and irinotecan-based (p=0.255) cytotoxic chemotherapy did not differ according to the KRAS mutation status. In addition, no significant difference in progression free survival (PFS; oxaliplatin, p=0.583 and irinotecan, p=0.426) and overall survival (OS; p=0.258) was observed between the wild and mutant type of the KRAS gene. In univariate and multivariate analyses, KRAS mutations did not have a major prognostic value regarding PFS (oxaliplatin: hazard ratio, 0.892; 95% confidence interval [CI], 0.590 to 1.347; p=0.586 and irinotecan: hazard ratio, 0.831;95% CI, 0.524 to 1.319; p=0.433) or OS (hazard ratio, 0.754; 95% CI, 0.460 to 1.236; p=0.263). In addition, anti-vascular endothelial growth factor therapies did not affect PFS to oxaliplatin or irinotecan and OS. Conclusion KRAS mutation is not a prognostic marker for PFS to oxaliplatin or irinotecan and OS in CRC patients who did not receive anti-EGFR therapies.
참고문헌 (24)
- Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- de Gramont A, "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer", J Clin Oncol, 18, pp.2938~2947 (2000)
- Saltz LB, "Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group", N Engl J Med, 343, pp.905~914 (2000)
- Vogelstein B, "Genetic alterations during colorectal-tumor development", N Engl J Med, 319, pp.525~532 (1988)
- Hamelin R, "Association of p53 mutations with short survival in colorectal cancer", Gastroenterology, 106, pp.42~48 (1994)
- Ahnen DJ, "Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study", Cancer Res, 58, pp.1149~1158 (1998)
- Schubbert S, "Hyperactive Ras in developmental disorders and cancer", Nat Rev Cancer, 7, pp.295~308 (2007)
- Amado RG, "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer", J Clin Oncol, 26, pp.1626~1634 (2008)
- Karapetis CS, "K-ras mutations and benefit from cetuximab in advanced colorectal cancer", N Engl J Med, 359, pp.1757~1765 (2008)
- Klump B, "Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature", Int J Colorectal Dis, 19, pp.23~42 (2004)
- Roth AD, "Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial", J Clin Oncol, 28, pp.466~474 (2010)
- Samowitz WS, "Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study", Cancer Epidemiol Biomarkers Prev, 9, pp.1193~1197 (2000)
- Ince WL, "Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab", J Natl Cancer Inst, 97, pp.981~989 (2005)
- Van Cutsem E, "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer", N Engl J Med, 360, pp.1408~1417 (2009)
- Anwar S, "Systematic review of genetic influences on the prognosis of colorectal cancer", Br J Surg, 91, pp.1275~1291 (2004)
- Locker GY, "ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer", J Clin Oncol, 24, pp.5313~5327 (2006)
- Gonzalez-Aguilera JJ, "Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colorectal cancer", Am J Clin Oncol, 27, pp.39~45 (2004)
- Westra JL, "Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients", J Clin Oncol, 23, pp.5635~5643 (2005)
- Andreyev HJ, "Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study", J Natl Cancer Inst, 90, pp.675~684 (1998)
- Andreyev HJ, "Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' stud", Br J Cancer, 85, pp.692~696 (2001)
- Leslie A, "Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas", Cancer Res, 63, pp.4656~4661 (2003)
- Baker SJ, "p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis", Cancer Res, 50, pp.7717~7722 (1990)
- Fearon ER, "A genetic model for colorectal tumorigenesis", Cell, 61, pp.759~767 (1990)
- Richman SD, "KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial", J Clin Oncol, 27, pp.5931~5937 (2009)